LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
NCT ID: NCT02888236
Last Updated: 2017-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
36 participants
INTERVENTIONAL
2016-09-30
2017-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LEO 32731 - A Phase I Study in Healthy Subjects
NCT02514694
LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects
NCT02126371
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
NCT00833872
Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfaction in Psoriasis Patients
NCT04765332
A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
NCT01116895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LEO 32731 tablet
LEO 32731 30 mg two times daily for 16 weeks
LEO 32731
LEO 32731 Placebo tablet
LEO 32731 placebo two times daily for 16 weeks
LEO 32731 Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LEO 32731
LEO 32731 Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged between 18 years and 65.
* Males or females of non-childbearing potential.
* Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis
* Have moderate to severe psoriasis vulgaris
* Candidates of systemic anti-psoriatic treatment and/or phototherapy
Exclusion Criteria
* Previously exposed to apremilast
* Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris
* Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandra Philipp, PhD
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité Universitätsmedizin Berlin, Dept. of Dermatology
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LP0058-1072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.